Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sanofi (NASDAQ:SNY)

Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sanofi (NASDAQ:SNY)

Sanofi reports positive phase 3 results for oral venglustat in type 3 Gaucher disease, matching standard therapy outcomes and supporting plans for global regulatory filings.

Mixed data mars Sanofi's venglustat programme

Sanofi has reported positive phase 3 results with venglustat in Gauder disease, but the drug missed the mark in a Fabry disease trial

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease

As its immunology work draws attention, Sanofi also pushes forward in rare disease

Sanofi markets a drug for certain Gaucher patients, but those with neurological problems tied to the disease have no available treatments.

Sanofi records win and loss with rare disease drug in Phase III trials

Sanofi’s venglustat showed a meaningful change in patients with Gaucher disease but not in patients with Fabry disease.The post Sanofi records win and loss with rare disease drug in Phase III trials appeared first on Clinical Trials Arena.